When endocrine therapy is needed, only tamoxifen should be used in premenopausal women [9], while aromatase inhibitors for years is the current treatment recommended in postmenopausal women 35 years or older who are at increased risk for breast cancer and low risk for adverse medication effects [10]. This evidence concerns the gene CYP19A1 and breast carcinoma.